Schrödinger to Participate in Upcoming Investor Conferences
NEW YORK, February 20, 2024--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in the following conferences in March:
TD Cowen 44th Annual Health Care Conference: Fireside chat on Tuesday, March 5, 2024 at 10:30 a.m. ET.
Leerink Partners Global Biopharma Conference: Fireside chat on Monday, March 11, 2024 at 12:40 p.m. E.T.
KeyBanc Life Sciences & MedTech Forum (Virtual): Fireside chat on Wednesday, March 20, 2024 at 10:30 a.m. E.T.
The live discussions can be accessed in the "Investors" section of Schrödinger’s website and will be archived for approximately 90 days.
About Schrödinger
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs.
Founded in 1990, Schrödinger has approximately 850 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220660242/en/
Contacts
Allie Nicodemo
Schrödinger, Inc.
allie.nicodemo@schrodinger.com
617-356-2325
